Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mesenchymal stem cells to enhance Anti-tumor activity of immunotherapy

A technology of mesenchymal stem cells and immune cells, applied in blood/immune system cells, antineoplastic drugs, genetically modified cells, etc., can solve problems such as inability to treat malignant tumors

Inactive Publication Date: 2018-11-23
APCETH GMBH & CO KG
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] Although adoptive cell therapy is effective in treating some cancers, including melanoma and leukemia / lymphoma, it remains ineffective in treating most other malignancies, especially most cases of solid cancers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mesenchymal stem cells to enhance Anti-tumor activity of immunotherapy
  • Mesenchymal stem cells to enhance Anti-tumor activity of immunotherapy
  • Mesenchymal stem cells to enhance Anti-tumor activity of immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0052] The immune system's primary response to tumors is to destroy abnormal cells using killer T cells, sometimes with the help of helper T cells. However, most tumors release products that suppress the immune response through various means and create an environment that normally hinders T cell activation. The present invention provides means to support anti-tumor immune responses in this setting by using MSCs as described herein.

[0053] The present invention is characterized by the surprising discovery that MSCs exhibit stimulating adjuvant properties relative to combined anti-tumor immunotherapies. In particular, the MSCs of the present invention do not contain transgenes expressing immunostimulatory cytokines or other immunostimulatory molecules, such as those that induce an antigen-independent immune response, resulting in enhanced efficacy of CAR-T cells against cancerous substances.

[0054] Responses to pathogens or cancerous tissue are coordinated through the compl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to mesenchymal stem cells (MSCs) for use in the treatment of a tumor, wherein said treatment comprises the combined administration of said mesenchymal stem cells with an anti-tumor immunotherapy, and wherein said MSCs do not comprise exogenous nucleic acids that encode immune response-stimulating cytokines. In a preferred embodiment the invention relates to the use of said MSCs in the treatment of a tumor and / or malignant disease, wherein the anti-tumor immunotherapy for combined administration comprises the administration of a cellular immunotherapy, preferably chimericantigen receptor (CAR) T cells, wherein said T cell receptor binds specifically to a tumor-associated antigen, and the mesenchymal stem cells are not genetically modified.

Description

[0001] describe [0002] The present invention relates to mesenchymal stem cells (MSCs) for use in the treatment of tumors, wherein said treatment comprises administration of said mesenchymal stem cells in combination with anti-tumor immunotherapy, and wherein said MSCs do not contain proteins encoding immune response stimulating cytokines exogenous nucleic acid. In an embodiment of the invention, the MSCs are not genetically modified, or are genetically modified to contain exogenous proteins that do not encode immunostimulatory cytokines and / or other immunostimulatory molecules that induce antigen-independent immune responses and / or stimulation. nucleic acid. [0003] In a preferred embodiment, the present invention relates to the use of said MSCs in the treatment of tumors and / or malignant diseases, wherein the anti-tumor immunotherapy for combined administration includes the administration of cellular immunotherapy, preferably the administration of chimeric antigen receptors...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0775C12N5/0783A61K35/28A61K35/17C07K16/30C12N5/077C07K14/54
CPCA61K35/17A61K35/28C07K16/3007C12N5/0636C12N5/0663C07K2319/00C12N2510/00C07K16/2827A61K2039/507C07K2317/622A61P35/00C12N5/0646A61K35/15A61K2300/00C07K2319/03A61K39/001182A61K2039/5156
Inventor 费利克斯·赫尔曼克里斯蒂安·根特尔乌尔夫·热曼
Owner APCETH GMBH & CO KG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com